Established August 2017
Click here for a short video on our SIG
The mission of the Digital Technology and Artificial Intelligence Special Interest Group (SIG) is to promote the incorporation of digital and artificial intelligence (AI) (including generative AI) technologies and tools within pharmacoepidemiological research in an ethical, transparent and scientifically rigorous manner so as to improve the efficiency and quality of real world evidence (RWE) generation. Specifically, the SIG seeks to:
Key definitions
Digital Technologies encompass a wide range of tools, systems, and methodologies that collect, process, and analyze data to support pharmacoepidemiologic research. This includes electronic medical records and claims data, patient-generated data (such as through mobile apps or surveys), wearable devices, synthetic data and other connected health technologies.
We define Artificial Intelligence (AI) as the use of computational methods and systems that simulate human intelligence to analyze data, identify patterns, and make decisions or predictions. In the context of pharmacoepidemiologic research, AI encompasses methods such as machine learning, natural language processing, and generative AI tools (including large language models (LLMs)), which enhance data analysis, real-world data/evidence generation, and study design.
Generative Artificial Intelligence (GenAI) is a subset of AI that focuses on creating new content such as text, images, audio, and software code that mimics human creativity and intelligence.
Please visit our ISPE Community for the latest SIG news, upcoming meetings, membership, documents library, connecting with SIG members and leaders, and more. An account is needed to access the community and join it.
Chair Vice Chair |
John Diaz-Decaro, PhD, MS Nivi Naidoo, MBChB, DipPEC, MPH, MSc CER |
Past Chair |
Meredith Smith, PhD, MPA, FISPE |